Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses
Go back to Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $9.23 | |||
| Open | $8.81 | 52 Week Low | $1.16 | |||
| Day High | $9.59 | P/E | N/A | |||
| Day Low | $8.81 | EPS | $-0.30 | |||
| Volume | 4,235,734 | |||||
